


# HPR-Data base on typical and atypical analgesics

## Investigated with Laser-EPs at HPR (>50 compounds)



# HPR

Human  
Pharmacodynamic  
Research

### NSAIDs

- Celecoxib
- Dexketoprofen trometamol
- Diclofenac i.v.
- Dipyrrone i.v. (metamizole)
- EP4 antagonist
- Etoricoxib
- Ibuprofen (racemic+enantiomer)
- Karprofen
- Ketorolac
- Lysine clonixinate
- Naproxen
- Parecoxib i.v.
- Rofecoxib
- Valdecoxib

### ASA+ASA-like

- ASA
- EBA (Ethoxy-benzoic acid)
- Ethenzamide
- Eugenol
- Paracetamol/ Acetaminophen

### Narcotics

- Cannabinoid agonists oral + i.v.
- Codeine
- Kappa agonist oral + i.v.
- Morphine
- Oxycodone
- Pentazocine oral + i.v.
- Remifentanyl i.v.
- Tramadol oral + i.v.
- Tapentadol
- Cannabinoid partial agonists oral\*\*

### H1-antagonists

- Dimethindene
- Diphenhydramine
- Orphenadrine i.v.
- ReN1869 (AH, amitripr.-like oral)

### Others

- Duloxetine (SSNRI oral)
- Ethanol oral + i.v.
- FAAH-Inhibitor
- Flupirtine (pyridine derivative oral)
- Nefopam
- Reboxetine (SNARI oral)
- ABT102 (TRPV1 antagonist oral)
- Z944 (T-type CCB oral)
- B1-antagonist (oral)\*\*
- Granisedron (5-HT<sub>3</sub> antagonist)\*\*
- Meprobamate\*
- N-type CCBs\*\* (oral)
- Propofol i.v.\*

• Compounds in red are not or minor effective in clinical pain conditions **and** in human experimental LEP settings\*

• Red & underlined are **Go-/No-Go-Decision studies\*\***

### Antiepileptics

- CM40907/Lodaxaprine (exp. AE, pyridazine derivative oral)
- Gabapentin
- Pregabalin
- Lacosamide\*

### Topicals

- ASA powder
- Dimethindene gel 0.1% (AH)
- DMSO solution + additives
- Lidocaine gel 2%,
- Lidocain solution 0.25% and lozenges (oral cavity)
- B1-antagonist\*\* (blocks bradykinin)
- NK1-antagonist\*\* (blocks substance P)